Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Yorvipath® (palopegteriparatide) – New orphan drug approval

August 12, 2024 - Ascendis Pharma announced the FDA approval of Yorvipath (palopegteriparatide), for the treatment of hypoparathyroidism in adults.

Download PDF

Rx navigation